New MRI Procedure Can Accurately Classify or Rule Out Suspected Prostate Carcinoma

A novel noninvasive Magnetic Resonance Imaging (MRI) method has been developed to detect or rule out prostate carcinomas.

The method, known as multi-parametric prostate MRI, enables physicians to probe prostate tissue cellular density, and anatomical features, and is the most reliable procedure currently available for accurate diagnosis of early-stage prostate carcinoma.

Prostate cancer is the second most common cause of death from cancer among men in the US, and the European Union, and an early accurate diagnosis helps minimizes the risk of adverse side effects, including incontinence, erectile dysfunction, and impotence.

Presently, patients that have a rising Prostate-Specific Antigen (PSA) value often undergo a Transrectal Ultrasound-guided (TRUS) biopsy. This method results in a 50% probability of detecting a carcinoma.

The new solution, developed by Siemens Healthcare (Erlangen, Germany), is the SEEit5, that includes Body 603 and Tim 4G coils and the Siemens RESOLVE application. The examination takes less than ten minutes, provides a highly accurate classification of the disease, and can rule out prostate cancer with a certainty of more than 89% percent. The SEEit5 solution uses the Siemens syngo MR E11 software architecture.

The radiologist reads and reports the results of the MRI scan using Siemens resyngo.via software, which supports the standard PI-RADS prostate cancer classification. The software displays the location of cancer-suspicious foci in a schematic drawing of the prostate.

Related Links:
Siemens Healthcare